Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1-30
SponsorBoston Children's Hospital

About this trial

The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide.

In childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Clinical diagnosis of progressive spasticity

Disqualifiers

None

Trial population

Male or female, under 30 years, with suspected HSP

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Identify Genetic Findings

Identifying genetic variants in patients with progressive spastic paraplegia

Time frame
An average of 1 year
2

Correlating Genetic Findings with HSP Phenotypes

Comparing phenotype/genotype associations via genome wide scanning

Time frame
An average of 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.